COVID-19 mRNA vaccine (BNT162) Qualitative and Quantitative Composition - Form to be diluted 30 µg/dose for adults and ≥12 years (purple cap)

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

This is a multidose vial with a purple cap and must be diluted before use. 

One vial (0.45 mL) contains 6 doses of 0.3 mL after dilution, see sections 4.2 and 6.6.

One dose (0.3 mL) contains 30 micrograms of tozinameran, a COVID-19 mRNA Vaccine (embedded in lipid nanoparticles).

Tozinameran is a single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2.

For the full list of excipients, see section 6.1.